Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7169928 | HARMONY | Non-imidazole alkylamines as histamine H3-receptor ligands and their therapeutic applications |
Feb, 2020
(4 years ago) | |
US8207197 | HARMONY | Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy] propyl] -piperidine |
Mar, 2030
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7910605 | HARMONY | Non-imidazole alkylamines as histamine H3- receptor ligands and their therapeutic applications |
Sep, 2022
(1 year, 7 months ago) | |
US8354430 | HARMONY | Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy]propyl]-piperidine |
Feb, 2026
(1 year, 9 months from now) | |
US8486947 | HARMONY | Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands |
Sep, 2029
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 14, 2024 |
Orphan Drug Exclusivity(ODE-255) | Aug 14, 2026 |
Orphan Drug Exclusivity(ODE-331) | Oct 13, 2027 |
New Indication(I-846) | Oct 13, 2023 |
NCE-1 date: 15 August, 2023
Market Authorisation Date: 14 August, 2019
Treatment: Method of treating cataplexy in patients with narcolepsy
Dosage: TABLET;ORAL